Core Viewpoint - The company, Enwei Pharmaceutical Co., Ltd., has announced a preliminary pricing for a share transfer through an inquiry process, with a determined price of 26.54 yuan per share [3]. Group 1: Share Transfer Details - The preliminary transfer price is set at 26.54 yuan per share based on inquiries conducted on January 27, 2026 [3][4]. - A total of 30 institutional investors participated in the inquiry, including fund management companies, securities firms, insurance companies, private fund managers, and qualified foreign investors, with a total effective subscription of 16,476,000 shares, resulting in a subscription multiple of 4.12 times [4]. - The shares to be transferred have been fully subscribed, with the preliminary designated buyers being 11 institutional investors, intending to acquire a total of 4,000,000 shares [4]. Group 2: Transfer Mechanism - The share transfer will not be conducted through centralized bidding or block trading, and it does not involve a reduction in holdings through the secondary market [3]. - The shares acquired through this inquiry transfer cannot be transferred by the buyers within six months after the acquisition [3]. Group 3: Governance and Control - The share transfer does not involve any change in the company's control and will not affect the company's governance structure or ongoing operations [6].
恩威医药股份有限公司股东询价转让定价情况提示性公告